BIOMAT Database Logo BIOMAT Database Logo

Protective effect of cytokines in mice to Pseudomonas aeruginosa infection. 1991

M Nakano, and K Onozuka, and K Sakamoto, and Y Nakano, and H Shinomiya, and T Saito-Taki
Department of Microbiology, Jichi Medical School, Tochigi, Japan.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008233 Lymphotoxin-alpha A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR. TNF Superfamily, Member 1,TNF-beta,Tumor Necrosis Factor Ligand Superfamily Member 1,Tumor Necrosis Factor-beta,Lymphotoxin,Lymphotoxin-alpha3,Soluble Lymphotoxin-alpha,alpha-Lymphotoxin,Lymphotoxin alpha,Lymphotoxin alpha3,Lymphotoxin-alpha, Soluble,Soluble Lymphotoxin alpha,Tumor Necrosis Factor beta,alpha Lymphotoxin
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea

Related Publications

M Nakano, and K Onozuka, and K Sakamoto, and Y Nakano, and H Shinomiya, and T Saito-Taki
Protective effect of Lactobacillus casei on Pseudomonas aeruginosa infection in mice.
May 1985, Infection and immunity,
M Nakano, and K Onozuka, and K Sakamoto, and Y Nakano, and H Shinomiya, and T Saito-Taki
[Protective effect of a corpuscular polyvalent Pseudomonas aeruginosa vaccine in generalized chronic Pseudomonas aeruginosa infection in mice with cyclophosphamide-induced leukopenia].
March 1986, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
M Nakano, and K Onozuka, and K Sakamoto, and Y Nakano, and H Shinomiya, and T Saito-Taki
Protective effect of baker's yeast mannan against Listeria monocytogenes and Pseudomonas aeruginosa infection in mice.
March 1990, Chemical & pharmaceutical bulletin,
M Nakano, and K Onozuka, and K Sakamoto, and Y Nakano, and H Shinomiya, and T Saito-Taki
Glycolipoprotein from Pseudomonas aeruginosa as a protective antigen against P. aeruginosa infection in mice.
November 1977, Infection and immunity,
M Nakano, and K Onozuka, and K Sakamoto, and Y Nakano, and H Shinomiya, and T Saito-Taki
Protective effect of pyocin against lethal Pseudomonas aeruginosa infections in mice.
April 1974, The Journal of infectious diseases,
M Nakano, and K Onozuka, and K Sakamoto, and Y Nakano, and H Shinomiya, and T Saito-Taki
Protective effect of saikosaponin A, saikosaponin D and saikogenin D against Pseudomonas aeruginosa infection in mice.
January 1990, International journal of immunopharmacology,
M Nakano, and K Onozuka, and K Sakamoto, and Y Nakano, and H Shinomiya, and T Saito-Taki
Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection.
January 1987, Infection,
M Nakano, and K Onozuka, and K Sakamoto, and Y Nakano, and H Shinomiya, and T Saito-Taki
Protective effect of recombinant murine granulocyte-macrophage colony-stimulating factor against Pseudomonas aeruginosa infection in leukocytopenic mice.
June 1989, Infection and immunity,
M Nakano, and K Onozuka, and K Sakamoto, and Y Nakano, and H Shinomiya, and T Saito-Taki
In vivo protective effect of lipopolysaccharide against Pseudomonas aeruginosa exotoxin A in mice.
May 1991, Infection and immunity,
M Nakano, and K Onozuka, and K Sakamoto, and Y Nakano, and H Shinomiya, and T Saito-Taki
Experimental infection with Pseudomonas aeruginosa in mice. I. The virulence of Pseudomonas aeruginosa for mice.
July 1971, Japanese journal of microbiology,
Copied contents to your clipboard!